LEAP-008: pembrolizumab plus lenvatinib after immunotherapy in non-small cell lung cancer
Koji Fukuda · 2025
Read LEAP-008: pembrolizumab plus lenvatinib after immunotherapy in non-small cell lung cancer by Koji Fukuda (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780427.txt.
Description
After immunotherapy stops working in lung cancer, doctors have little to offer. Koji Fukuda discussed in 2025 a phase III trial that tried to rescue such patients by continuing immunotherapy and adding a blood-vessel drug.
The LEAP-008 trial pitted pembrolizumab plus lenvatinib against standard docetaxel in patients who had progressed after platinum chemotherapy and checkpoint blockade. Survival and progression endpoints were not met: both arms landed near eleven to twelve months of overall survival, and response rates barely differed. Side effects and dropouts ran higher with the combination. Fukuda reads the failure as evidence that beating chemotherapy after immunotherapy remains hard.
Catalog record
| CREATOR | Koji Fukuda |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |